Tag: patient dosing

Phase-II of the ATH434 trial for multiple system atrophy patient dosing has started, according to Alterity Therapeutics.

The first participant in Alterity Therapeutics’ phase 2 clinical trial of ATH434 in multiple system atrophy (MSA), a rare and severely handicapping Parkinson’s disease, has been dosed in the US, according to the biotechnology company’s announcement. Alterity Therapeutics is dedicated…

Occlutech starts patient dosing in the FROST study to look into using an atrial flow regulator to treat heart failure with preserved ejection fraction (HFpEF).

One of the top manufacturers of minimally invasive structural heart disease devices, Occlutech Holding AG (Occlutech), has announced the enrollment of the first patient in the FROST-HF study. In the FROST-HF study, patients with heart failure with either preserved ejection…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds